Provided by Tiger Trade Technology Pte. Ltd.

Royalty Pharma plc

61.31
+0.73001.21%
Post-market: 61.310.00000.00%19:30 EDT
Volume:2.33M
Turnover:142.36M
Market Cap:35.37B
PE:32.89
High:61.60
Open:60.53
Low:60.37
Close:60.58
52wk High:62.13
52wk Low:34.08
Shares:576.94M
Float Shares:392.53M
Volume Ratio:0.94
T/O Rate:0.59%
Dividend:0.91
Dividend Rate:1.48%
EPS(TTM):1.86
EPS(LYR):1.78
ROE:13.97%
ROA:5.09%
PB:5.18
PE(LYR):34.42

Loading ...

Royalty Pharma to join Goldman Sachs Global Healthcare Conference fireside chat

Reuters
·
Jun 05

Royalty Pharma shareholders elect nine directors at annual meeting

Reuters
·
Jun 05

Royalty Pharma CFO Terrance P. Coyne disposes of 64,399 shares worth $3.48 million

Reuters
·
May 29

BRIEF-Royalty Pharma - Enters Revolving Credit Agreement On May 22, 2026

Reuters
·
May 29

Royalty Pharma - Revolving Credit Facility to Mature on May 22, 2031 - SEC Filing

THOMSON REUTERS
·
May 29

Royalty Pharma - Credit Agreement Provides for $1.8 Bln Unsecured Revolving Credit Facility - SEC Filing

THOMSON REUTERS
·
May 29

Royalty Pharma signs USD 1.8 billion revolving credit facility, refinancing 2021 loan agreement

Reuters
·
May 29

How Investors May Respond To Royalty Pharma (RPRX) Strong Q1 Royalties And Expanding Biotech Partnerships

Simply Wall St.
·
May 28

Royalty Pharma EVP Marshall Urist sells 13,684 shares for $721,846.84

Reuters
·
May 22

Royalty Pharma EVP Marshall Urist sells 13,684 shares for $726,150.99

Reuters
·
May 16

Royalty Pharma Director Gregory Norden sells 3,045 shares for $161,385

Reuters
·
May 16

Royalty Pharma to present at BofA Securities Healthcare Conference webcast

Reuters
·
May 08

Royalty Pharma Is Maintained at Buy by Citigroup

Dow Jones
·
May 08

Bank of America Securities Keeps Their Buy Rating on Royalty Pharma (RPRX)

TIPRANKS
·
May 07

Royalty Pharma price target raised to $66 from $50 at Citi

TIPRANKS
·
May 07

Royalty Pharma (RPRX) Gets a Buy from TD Cowen

TIPRANKS
·
May 07

Royalty Pharma Q1 Adj. EPS $1.30 Beats $1.21 Estimate, Sales $631.000M Miss $1.235B Estimate

Benzinga Earnings
·
May 06

Royalty Pharma Q1 Net Income, Revenue Rise

MT Newswires Live
·
May 06

Royalty Pharma Q1 adjusted EBITDA climbs 21% to $889 million; portfolio receipts rise 10% to $925 million

Reuters
·
May 06

Royalty Pharma - Raises FY2026 Portfolio Receipts Guidance to $3.325 Bln-$3.45 Bln

THOMSON REUTERS
·
May 06